Production Development
Recent advancements in monoclonal antibody production have focused on combining mouse cells with human cells. This innovation significantly reduces the likelihood of rejection by human immune systems, as the body's cells can recognize the genetic material from both sources.
Example: The hybridoma technique now incorporates human cellular material to create more compatible antibodies for human treatment.
Highlight: The integration of human cells represents a significant advancement in making treatments more effective and safer for patients.


































